shares of miners, glencore going up 27% in 2022 with bhp also following onaround a 30% growth picture out on that front, outperforming last year. but the question on this one is whether that high dividend that bhp usually puts out is enough to keep investors sort of into that stock for the remainder then of 2023 will they get into that as they did last year outperforming, however, was the key factor not everything has been green, of course, in 2022 we saw the likes of the homebuilders go down they were all in the red for the most part. this was really around those recessionary fears, the high inflation numbers we saw people not necessarily going into the home market it's been affected quite dramatically you've seen around 47% retailers are the ones, however, to take note of. you look at the data not too long ago, coming up around 8:00, uk retailers are in a lot of trouble over 17,000 shops were closed in the year 2022. that's the worst year in five years and pretty much nearly 50 stores closing every day with over 150,000 jobs lost in the high street and other private retailers as wel

. >> glencore. it was a great stock last year, valuation's still cheap.ll cheap. a lot of runway there. my sort of recessionary fierce are already priced in, val -- fears are already priced in. you've got to own europe, stu. stuart: maybe i should go back and buy some -- [laughter] >> sell that microsoft today. stuart: no, no, not doing that. that would be a headline -- what's the name of that company? >> glencore. stuart: give me another one. >> okay. so i also like, i like royal dutch. anything energy related in europe trades at a discount to the u.s. energy companies, and we know right now energy is not going can away. the need for fossil fuels is going to be huge. dividend yield's very attractive, much cheaper than u.s. energy stocks. gotta own it in your portfolio. stuart it's been a long time since we've had a guest saying put your money in britain. >> i wanted blow your mind morning. stuart: you did it, son. all right. the opening bell will ring in literally 9 or 7 or 8 seconds, and we'll take -- there you are. they're clapping and cheering. it is

part of that is due to astrazeneca and also glencore.rms of sectors, technology leading the pack, getting 0.5%. insurance also up 0.5%. six sectors in the red, energy at the bottom of the list. francine: the biden administration is confronting china with evidence that chinese a company's could be assisting russia's war effort in ukraine. we are joined by bloomberg's senior reporter for international affairs. this is surprising, but did it surprise you given their neutral stance on the war? mark: it is not especially surprising -- marck: it is not especially surprising. the u.s. is letting this be known quietly. it is a delicate balance china has taken from the beginning. they are strategic partners with russia. it is a serious relationship, personal between president xi and president putin. more recently they let it be known they were upset that president putin had not given him forewarning of the invasion, but nevertheless they have tried to balance all the way through the position of being at the same time russia's greatest ally and ne

ftse 100 is leaping higher as well .10% higher over there we see a bounce in glencore we will get a lot of results from the retailers that is something to watch out for in the uk basket switching to fx. we saw a dip in the u.s. dollar. that weakness is continuing today. the euro is a quarter of a percentage point firmer against the u.s. dollar. the pound is moving higher .60% firmer. 122. shy of that. dollar/yen, we spoke with elsa earlier, saying dollar/yen is the space for longer term. we will continue to see if this has legs and the yuan with the china reopening. it is also stronger against the dollar to the tune of .5%. as for u.s. futures, all of the futures are opening up in positive territory dow up 70. nasdaq up 50 worth mentioning friday was the best day for u.s. markets since november 30th. >>> let's take a closer look at the pharma sector. a new drug approved for alzheimer's patients to slow the rate of decline in early stages. the drug developed by biogen is one of the first of its kind for alzheimer's, but could be difficult to access with the cost of over $26,000 per year.

he liked rio, bhp, glencore. where are you on those. >> we own a position in rio, and we disclosed that. we like the asset quality that we have there. but you are right. those types of moves have gone up substantially, which makes a valuation case harder than it was a few months ago. but as a value manager, we are looking at where they are positioned in the commodity complex. we are trying to make sure we have a good combination of companies that are dependent on commodity prices, but they also have something they can do internally that will drive earnings, in addition to realizing the benefits of the commodity cost moves, both up and down. >> can you go a little further where they are exposed? where you want them exposed, and where you want them not expose? >> i think we can look at something like the copper market, which people are structurally bullish on, and we are seeing some signs that is coming into balance, and what does that mean? you are likely to have some level of usher on prices. the balance is ok. i